BioSpace News Archive

AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.

Cardiovascular disease can play a significant role in the severity of various urologic conditions, and treating various urologic conditions can considerably affect cardiovascular health.

Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten Supporting Progression to Phase 3 Clinical Trial Additional Results from GALACTIC-HF Show Effect of Treatment with Omecamtiv Mecarbil in Black Patients Consistent with Overall Population and White Patients Cytokinetics to Host Investor/Media Event and Webcast on September 13, 2021 at 8:30 AM Eastern Time SOU

BeiGene, Ltd., a global biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that clinical results and subgroup analyses from the Company’s robust lung cancer program will be presented at the European Society for Medical Oncology Congress 2021.

EMD Serono announced research from Company-sponsored, investigator-sponsored, and collaborative studies — including two oral and two mini-oral presentations — at this year’s World Conference on Lung Cancer, September 8-14, 2021, and the European Society for Medical Oncology Congress, September 16-21, 2021.

BioXcel Therapeutics, Inc. announced that updates from its ongoing Phase 1b/2 trial of BXCL701, the Company’s investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the 2021 European Society for Medical Oncology Congress, which will take place virtually from September 16-21, 2021.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody, in first-line HER2-expressing GEA.

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced poster presentations relating to multiple investigational product candidates at the European Society for Medical Oncology Virtual Conference, taking place September 16-21, 2021.